|
1
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J and
Thun MJ: Cancer statistics, 2009. CA Cancer J Clin. 59:225–249.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Reiman JM, Kmieciak M, Manjili MH and
Knutson KL: Tumor immunoediting and immunosculpting pathways to
cancer progression. Semin Cancer Biol. 17:275–287. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Smyth MJ, Dunn GP and Schreiber RD: Cancer
immunosurveillance and immunoediting: The roles of immunity in
suppressing tumor development and shaping tumor immunogenicity. Adv
Immunol. 90:1–50. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Carosella ED, HoWangYin KY, Favier B and
LeMaoult J: HLA-G-dependent suppressor cells: Diverse by nature,
function, and significance. Hum Immunol. 69:700–707. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pietra G, Romagnani C, Manzini C, Moretta
L and Mingari MC: The emerging role of HLA-E-restricted
CD8+ T lymphocytes in the adaptive immune response to
pathogens and tumors. J Biomed Biotechnol. 2010:9070922010.
View Article : Google Scholar
|
|
6
|
Yan WH: HLA-G expression in hematologic
malignancies. Expert Rev Hematol. 3:67–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Lepin EJ, Bastin JM, Allan DS, et al:
Functional characterization of HLA-F and binding of HLA-F tetramers
to ILT2 and ILT4 receptors. Eur J Immunol. 30:3552–3561. 2000.
View Article : Google Scholar
|
|
8
|
Zhang J, Pan L, Chen L, Feng X, Zhou L and
Zheng S: Non-classical MHC-Iota genes in chronic hepatitis B and
hepatocellular carcinoma. Immunogenetics. 64:251–258. 2012.
View Article : Google Scholar
|
|
9
|
Noguchi K, Isogai M, Kuwada E, Noguchi A,
Goto S and Egawa K: Detection of anti-HLA-F antibodies in sera from
cancer patients. Anticancer Res. 24:3387–3392. 2004.PubMed/NCBI
|
|
10
|
Ishak KG, Anthony PP and Sobin LH:
Histological Typing of Tumors of the Liver. 2nd edition. Springer;
Berlin: 1994, View Article : Google Scholar
|
|
11
|
Edge SB and Compton CC: The American Joint
Committee on Cancer: the 7th edition of the AJCC cancer staging
manual and the future of TNM. Ann Surg Oncol. 17:1471–1474. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin A, Zhang X, Ruan YY, Wang Q, Zhou WJ
and Yan WH: HLA-F expression is a prognostic factor in patients
with non-small-cell lung cancer. Lung Cancer. 74:504–509. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhang X, Lin A, Zhang JG, et al:
Alteration of HLA-F and HLA I antigen expression in the tumor is
associated with survival in patients with esophageal squamous cell
carcinoma. Int J Cancer. 132:82–89. 2013. View Article : Google Scholar
|
|
14
|
Zhang JG, Zhang X, Lin A and Yan WH:
Lesion HLA-F expression is irrelevant to prognosis for patients
with gastric cancer. Hum Immunol. 74:828–832. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ishigami S, Arigami T, Setoyama T, et al:
Clinical-pathological implication of human leukocyte
antigen-F-positive gastric adenocarcinoma. J Surg Res. 184:802–806.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Geraghty DE, Wei XH, Orr HT and Koller BH:
Human leukocyte antigen F (HLA-F). An expressed HLA gene composed
of a class I coding sequence linked to a novel transcribed
repetitive element. J Exp Med. 171:1–18. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Geraghty DE: Structure of the HLA class I
region and expression of its resident genes. Curr Opin Immunol.
5:3–7. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Boyle LH, Gillingham AK, Munro S and
Trowsdale J: Selective export of HLA-F by its cytoplasmic tail. J
Immunol. 176:6464–6472. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wainwright SD, Biro PA and Holmes CH:
HLA-F is a predominantly empty, intracellular, TAP-associated MHC
class Ib protein with a restricted expression pattern. J Immunol.
164:319–328. 2000. View Article : Google Scholar
|
|
20
|
Lee N and Geraghty DE: HLA-F surface
expression on B cell and monocyte cell lines is partially
independent from tapasin and completely independent from TAP. J
Immunol. 171:5264–5271. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lee N, Ishitani A and Geraghty DE: HLA-F
is a surface marker on activated lymphocytes. Eur J Immunol.
40:2308–2318. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ishitani A, Sageshima N, Lee N, et al:
Protein expression and peptide binding suggest unique and
interacting functional roles for HLA-E, F, and G in
maternal-placental immune recognition. J Immunol. 171:1376–1384.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Goodridge JP, Lee N, Burian A, et al:
HLA-F and MHC-I open conformers cooperate in a MHC-I antigen
cross-presentation pathway. J Immunol. 191:1567–1577. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Shobu T, Sageshima N, Tokui H, et al: The
surface expression of HLA-F on decidual trophoblasts increases from
mid to term gestation. J Reprod Immunol. 72:18–32. 2006. View Article : Google Scholar : PubMed/NCBI
|
